Skip to main content
Veterinary Medicines

Gujatal 100 mg/ml, solution for infusion for horses

Authorised
  • Guaifenesin

Product identification

Medicine name:
Gujatal 100 mg/ml, solution for infusion for horses
MYORELAX 100 MG/ML SOLUTION POUR PERFUSION POUR CHEVAUX
Active substance:
  • Guaifenesin
Target species:
  • Horse
Route of administration:
  • Intravenous use

Product details

Active substance and strength:
  • Guaifenesin
    100.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for infusion
Withdrawal period by route of administration:
  • Intravenous use
    • Horse
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM03BX90
Authorisation status:
  • Valid
Authorised in:
  • France
Package description:
  • 500 ml polypropylene bottle with a bromobutyl rubber stop and aluminium cap

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Eurovet Animal Health B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Eurovet Animal Health B.V.
Responsible authority:
  • French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
  • FR/V/8812222 1/2012
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0162/001
Concerned member states:
  • France
  • Germany
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 27/05/2024

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 18/06/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."